Lidokain/Adrenalin Aguettant

Lidocaine hydrochloride, the active ingredient in Lidokain/Adrenalin Aguettant, is a local anesthetic presented as a sterile solution for epidural, infiltration, and perineural use. It provides rapid onset of numbness and, together with epinephrine, prolongs the anesthetic effect for surgical and diagnostic procedures in adult patients. GNH USA supplies Lidokain/Adrenalin Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidokain/Adrenalin Aguettant is used in the local anesthetic pathway to provide targeted numbness for various procedures. - Surgical procedures: produces reliable local anesthesia for incision and excision work. - Epidural analgesia: delivers prolonged pain relief during labor or postoperative recovery. - Perineural nerve block: facilitates temporary nerve conduction block for diagnostic or therapeutic purposes.

Adverse reactions may occur following administration of Lidokain/Adrenalin Aguettant.

Common Side Effects: - Tingling or numbness at the injection site. - Mild transient increase in heart rate. - Localized swelling or bruising. - Headache. - Nausea. - Dizziness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Cardiac arrhythmias or tachycardia. - Hypotension or hypertension extremes. - Seizures. - Methemoglobinemia. - Persistent numbness beyond expected duration.

Before using Lidokain/Adrenalin Aguettant, consider the following safety measures. - Patient assessment: evaluate cardiac history and allergy status. - Dosage calculation: ensure dose does not exceed recommended maximum for combined agents. - Monitoring: observe vital signs during and after administration. - Drug interactions: review concomitant medications that affect catecholamine levels. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at below 25°C: keep in original packaging, protect from light and moisture.

Lidokain/Adrenalin Aguettant may interact with other medicines; awareness helps prevent adverse events.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may enhance epinephrine‑induced hypertension. - Class I antiarrhythmics (e.g., quinidine): increase risk of lidocaine toxicity. - Monoamine oxidase inhibitors: potentiate catecholamine effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise lidocaine plasma levels. - Diuretics: can alter electrolyte balance affecting cardiac response. - Other local anesthetics: cumulative toxicity risk.